Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study - Scorecard - MDSpire
Advertisement
Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study
Clinical Scorecard: Combination of Radiotherapy and Immunotherapy, With or Without Chemotherapy, Enhances Survival in Older Patients with Esophageal Squamous Cell Carcinoma: A Comorbidity-Adjusted Real-World Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Combination of radiotherapy with immunotherapy enhances survival through immunogenic cell death and T-cell activation, requiring further validation.
Target Population
Care Setting
Key Highlights
RIT ± CT regimen associated with reduced mortality risk (HR = 0.341, P = 0.029); findings are exploratory and need validation.
Patients with medium CIRS-G scores (4–6) showed the most significant OS benefit.
Grade ≥3 treatment-related adverse events (TRAEs) highest in RIT ± CT group (55.0%).
No treatment-related deaths reported.
Guideline-Based Recommendations
Diagnosis
Management
Consider multimodal treatment strategies including radiotherapy and immunotherapy for elderly patients.
Utilize CIRS-G scores for patient stratification.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
CIRS-G score can help identify optimal candidates for multimodal therapy, guiding treatment decisions.
Clinical Best Practices
Utilize a multidisciplinary team for treatment decision-making.
Assess comorbidity burden using CIRS-G for better treatment stratification.
Ensure comprehensive monitoring of adverse events during treatment.
Consider patient comorbidities in treatment planning.
